Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 4/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | BCR | P11274 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13515311 | 0.94 | PIM3 (0.54) | PIM3BRAFDYRK1ATTKRAF1 | |
| SCHEMBL2933931 | 0.90 | PIM3 (0.53) | PIM3BRAFDYRK1ATTKRAF1 | |
| Trifluoroacetic Acid SCHEMBL2931457 | 0.89 | FASN (0.46) | PIM3DYRK1AMKNK1MKNK2ABL1 | |
| Trifluoroacetic Acid SCHEMBL2935027 | 0.89 | MKNK1 (0.41) | PIM3DYRK1AMKNK1MKNK2ABL1 | |
| SCHEMBL2934437 | 0.87 | TTK (0.52) | PIM3BRAFDYRK1ATTKRAF1 | |
| SCHEMBL13515277 | 0.83 | FASN (0.50) | PIM3BRAFMKNK1MKNK2ABL1 | |
| SCHEMBL13515300 | 0.82 | MKNK1 (0.46) | BRAFMKNK1MKNK2ABL1BCR | |
| Trifluoroacetic Acid SCHEMBL2970750 | 0.82 | PIM3 (0.46) | PIM3BRAFRAF1 | |
| SCHEMBL2928592 | 0.81 | PIM3 (0.71) | PIM3BRAFRAF1CHEK1 | |
| SCHEMBL2932525 | 0.80 | LRRK2 (0.46) | BRAFTTKMKNK1MKNK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | PIM3 2131/4885BRAF 524/4885DYRK1A 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.